SCHEMBL19601215

SCHEMBL19601215

CC(C)P(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 7/20 0.80
P2RY2 P41231 3/20 0.80
SRC P12931 2/20 0.80
SMN1; SMN2 Q16637 2/20 0.80
TRPM2 O94759 2/20 0.80
TAS1R3 Q7RTX0 2/20 0.80
TAS1R1 Q7RTX1 2/20 0.80
DNPH1 O43598 1/20 0.80
PRKAB2 O43741 1/20 0.80
LDHA P00338 1/20 0.80
ADRB2 P07550 1/20 0.80
FBP1 P09467 1/20 0.80
ADORA1 P30542 1/20 0.80
PRKAG1 P54619 1/20 0.80
PRKAA2 P54646 1/20 0.80
PDE4D Q08499 1/20 0.80
KCNH2 Q12809 1/20 0.80
PRKAA1 Q13131 1/20 0.80
PDE3A Q14432 1/20 0.80
P2RY11 Q96G91 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13966729 0.93 P2RY1 (0.84) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL638702 0.90 P2RY1 (0.80) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL9751898 0.89 P2RY1 (0.85) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL26757324 0.89 P2RY1 (0.85) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL9331203 0.89 P2RY1 (0.85) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL14391813 0.89 P2RY1 (0.85) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL132458 0.89 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL19420134 0.89 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL20277555 0.89 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2
Adenosine Phosphate SCHEMBL13170051 0.89 P2RY1 (1.00) P2RY1P2RY2SRCSMN1; SMN2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151401-A1 METHOD OF REDUCING AND RECYCLING OXIDIZED FLAVIN COFACTORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-05-18 US disclosed
US-20170327549-A1 Adenylation Enzyme Inhibitors STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) 2017-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327549-A1 Adenylation Enzyme Inhibitors ADSL, APEH, AHCY P2RY1 1310/4885P2RY2 1931/4885SRC 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.